Interstitial lung diseases (ILDs) are a heterogeneous group of conditions characterized by inflammation and fibrosis of the lung interstitium. They represent a significant diagnostic and therapeutic challenge in pulmonary medicine due to their complex pathophysiology and variable clinical presentation.
ILDs are primarily disorders of the lung interstitium, involving the alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues. Inflammatory and immune responses lead to tissue damage, fibroblast proliferation, and extracellular matrix deposition, resulting in irreversible lung fibrosis and impaired gas exchange.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. The disease progression varies widely, from slow deterioration over years to a rapid decline within months.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, allowing detailed visualization of the lung parenchyma. Pulmonary function tests reveal a restrictive pattern with reduced lung volumes and diffusing capacity. Bronchoalveolar lavage and surgical lung biopsy may be required in certain cases for definitive diagnosis.
Management of ILDs is multifaceted, involving pharmacological and non-pharmacological interventions. Corticosteroids and immunosuppressive agents are the mainstay of treatment for most ILDs. Antifibrotic agents have shown promise in idiopathic pulmonary fibrosis. Lung transplantation may be considered in advanced stages. Patient education, pulmonary rehabilitation, and palliative care play crucial roles in improving quality of life.
Understanding the complex nature of ILDs is crucial for timely diagnosis and appropriate management. Increased awareness about these conditions among healthcare professionals can significantly improve patient outcomes. Continued research is needed to further elucidate the pathophysiology of ILDs and develop more effective therapeutic strategies.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation